Clinical Trials

China’s Rise in Drug Development Looms Over U.S. - The New York Times

Sun, 31 May 2026 15:57:36 GMT

China’s Rise in Drug Development Looms Over U.S. The New York Times

After new drug’s ‘unprecedented’ results for pancreatic cancer, doctors look at other uses - NBC News

Sun, 31 May 2026 12:00:00 GMT

After new drug’s ‘unprecedented’ results for pancreatic cancer, doctors look at other uses NBC News

Revolution's pancreatic cancer drug doubles survival, boosts quality of life - Reuters

Sun, 31 May 2026 13:40:03 GMT

Revolution's pancreatic cancer drug doubles survival, boosts quality of life Reuters

ASCO: Lilly exec points to ‘nutty’ 100% response rate for in vivo CAR-T as justifying Kelonia buyout - Fierce Biotech

Sun, 31 May 2026 12:00:00 GMT

ASCO: Lilly exec points to ‘nutty’ 100% response rate for in vivo CAR-T as justifying Kelonia buyout Fierce Biotech

Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China - Yahoo Finance

Sun, 31 May 2026 13:06:00 GMT

Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China Yahoo Finance

Clinical trial seeks to advance intuitive assistive robotics for people with paralysis - Rice University

Thu, 28 May 2026 14:00:31 GMT

Clinical trial seeks to advance intuitive assistive robotics for people with paralysis Rice University

New cancer jab returns ‘unprecedented’ results in major clinical trial - The Independent

Sun, 31 May 2026 08:26:00 GMT

New cancer jab returns ‘unprecedented’ results in major clinical trial The Independent

Cardiovascular Safety of Next-Generation Antibody-Drug Conjugates in HER2-Low and Triple-Negative Breast Cancer: A Narrative Review (2020-2025) - The Cureus Journal of Medical Science

Sun, 31 May 2026 13:39:30 GMT

Cardiovascular Safety of Next-Generation Antibody-Drug Conjugates in HER2-Low and Triple-Negative Breast Cancer: A Narrative Review (2020-2025) The Cureus Journal of Medical Science

Study: New Drug Could Dramatically Increase Pancreatic Cancer Survival | Newswise - Newswise

Sun, 31 May 2026 21:45:00 GMT

Study: New Drug Could Dramatically Increase Pancreatic Cancer Survival | Newswise Newswise

Daraxonrasib, second-line pancreatic cancer treatment, 'truly remarkable' | 2026 ASCO - Managed Healthcare Executive

Sun, 31 May 2026 12:08:47 GMT

Daraxonrasib, second-line pancreatic cancer treatment, 'truly remarkable' | 2026 ASCO Managed Healthcare Executive

James Wu: Follow Charles Jiang for Great Insights on Clinical Trials and Research Studies! - Oncodaily

Sun, 31 May 2026 22:45:03 GMT

James Wu: Follow Charles Jiang for Great Insights on Clinical Trials and Research Studies! Oncodaily

Phase 1 clinical trials, explained: 11 things to know - UT MD Anderson

Fri, 29 May 2026 12:15:56 GMT

Phase 1 clinical trials, explained: 11 things to know UT MD Anderson

Women Underrepresented as Authors of Phase 3 Solid Tumor Trials Presented at ASCO Annual Meeting - Oncology News Central

Sun, 31 May 2026 10:49:49 GMT

Women Underrepresented as Authors of Phase 3 Solid Tumor Trials Presented at ASCO Annual Meeting Oncology News Central

The Neurodegenerative Trial Problem Has a Design Solution—But Sponsors Keep Ignoring It - The Clinical Trial Vanguard

Sun, 31 May 2026 06:39:43 GMT

The Neurodegenerative Trial Problem Has a Design Solution—But Sponsors Keep Ignoring It The Clinical Trial Vanguard

Dr. Sam Poore to lead clinical trials education program - University of Wisconsin–Madison

Fri, 29 May 2026 19:14:19 GMT

Dr. Sam Poore to lead clinical trials education program University of Wisconsin–Madison

The eCOA Iceberg: Uncovering The Hidden Costs Of Software-Only Models - Clinical Leader

Sun, 31 May 2026 21:33:45 GMT

The eCOA Iceberg: Uncovering The Hidden Costs Of Software-Only Models Clinical Leader

Abemaciclib Produces First Positive Phase 3 Trial Result in Dedifferentiated Liposarcoma - OncLive

Sun, 31 May 2026 23:01:04 GMT

Abemaciclib Produces First Positive Phase 3 Trial Result in Dedifferentiated Liposarcoma OncLive

Why Trump reversed course to fast-track psychedelic drugs for mental healthcare - CNBC

Sun, 31 May 2026 12:00:02 GMT

Why Trump reversed course to fast-track psychedelic drugs for mental healthcare CNBC

MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial - Nature

Sun, 31 May 2026 16:21:48 GMT

MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial Nature

Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer - PR Newswire

Sun, 31 May 2026 12:01:00 GMT

Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer PR Newswire

How Daraxonrasib Could Improve Pancreatic Cancer Treatment, Offering New Hope - Memorial Sloan Kettering Cancer Center

Sun, 31 May 2026 04:00:00 GMT

How Daraxonrasib Could Improve Pancreatic Cancer Treatment, Offering New Hope Memorial Sloan Kettering Cancer Center

Bezuclastinib Plus Sunitinib Improves Survival in GIST - Oncology News Central

Sun, 31 May 2026 17:40:24 GMT

Bezuclastinib Plus Sunitinib Improves Survival in GIST Oncology News Central

After a brachytherapy clinical trial, stage 4 melanoma is now cancer-free - UT MD Anderson

Sat, 30 May 2026 12:12:48 GMT

After a brachytherapy clinical trial, stage 4 melanoma is now cancer-free UT MD Anderson

GammaTile Shows 26-Point Survival Gain Over Surgery Alone in Brain Metastases Trial - The Clinical Trial Vanguard

Sun, 31 May 2026 06:54:44 GMT

GammaTile Shows 26-Point Survival Gain Over Surgery Alone in Brain Metastases Trial The Clinical Trial Vanguard

Novel ADC Combo Shows Efficacy in Phase 2 Bladder Cancer Data - Oncology News Central

Sun, 31 May 2026 17:24:10 GMT

Novel ADC Combo Shows Efficacy in Phase 2 Bladder Cancer Data Oncology News Central

Pumitamig shows 72.7% response rate in Phase 2 squamous NSCLC trial - The Clinical Trial Vanguard

Sun, 31 May 2026 06:54:44 GMT

Pumitamig shows 72.7% response rate in Phase 2 squamous NSCLC trial The Clinical Trial Vanguard

Perioperative Apalutamide in High-Risk Localized or Locally Advanced Prostate Cancer Reduces Risk of Metastasis and Death | Newswise - Newswise

Sun, 31 May 2026 12:30:00 GMT

Perioperative Apalutamide in High-Risk Localized or Locally Advanced Prostate Cancer Reduces Risk of Metastasis and Death | Newswise Newswise

RAS(ON) Inhibitor Doubles Median Overall Survival in Results of Phase 3 Trial for Patients with Metastatic Pancreatic Cancer | Newswise - Newswise

Sun, 31 May 2026 12:15:00 GMT

RAS(ON) Inhibitor Doubles Median Overall Survival in Results of Phase 3 Trial for Patients with Metastatic Pancreatic Cancer | Newswise Newswise

Research Rising: Recognizing Clinical Trials Day 2026 - Pfizer

Mon, 25 May 2026 15:56:09 GMT

Research Rising: Recognizing Clinical Trials Day 2026 Pfizer

New T-cell engager shows promise for advanced solid tumors - Medical Xpress

Sun, 31 May 2026 14:00:02 GMT

New T-cell engager shows promise for advanced solid tumors Medical Xpress

Pediatric Oncology Keeps Getting Treated as an Afterthought. The Biology Disagrees. - The Clinical Trial Vanguard

Sat, 30 May 2026 06:44:36 GMT

Pediatric Oncology Keeps Getting Treated as an Afterthought. The Biology Disagrees. The Clinical Trial Vanguard

EFS Improves With Selpercatinib in RET+ NSCLC Trial - CancerNetwork

Sun, 31 May 2026 15:06:52 GMT

EFS Improves With Selpercatinib in RET+ NSCLC Trial CancerNetwork

Patients, doctors hail ‘revolutionary’ new drug for pancreatic cancer - WBEZ Chicago

Sun, 31 May 2026 10:00:00 GMT

Patients, doctors hail ‘revolutionary’ new drug for pancreatic cancer WBEZ Chicago

Navigating Regulatory Obstacles to AI Adoption in Clinical Trials - Lab Manager

Sat, 30 May 2026 03:47:11 GMT

Navigating Regulatory Obstacles to AI Adoption in Clinical Trials Lab Manager

FDA’s May 2026 Leadership Exodus: What the Simultaneous CDER and CBER Vacancies Mean for Sponsor IND Strategy - The Clinical Trial Vanguard

Sat, 30 May 2026 14:19:36 GMT

FDA’s May 2026 Leadership Exodus: What the Simultaneous CDER and CBER Vacancies Mean for Sponsor IND Strategy The Clinical Trial Vanguard

GRAIL’s Galleri Trial Misses Primary Endpoint but Shows Stage IV Cancer Reduction - The Clinical Trial Vanguard

Sun, 31 May 2026 06:54:44 GMT

GRAIL’s Galleri Trial Misses Primary Endpoint but Shows Stage IV Cancer Reduction The Clinical Trial Vanguard

Sacituzumab tirumotecan plus pembrolizumab meets primary endpoint in lung cancer trial - The Clinical Trial Vanguard

Sun, 31 May 2026 06:49:44 GMT

Sacituzumab tirumotecan plus pembrolizumab meets primary endpoint in lung cancer trial The Clinical Trial Vanguard

BioXcel’s BXCL501 Shows Efficacy Across Severity Levels in At-Home Agitation Trial - The Clinical Trial Vanguard

Sun, 31 May 2026 06:54:44 GMT

BioXcel’s BXCL501 Shows Efficacy Across Severity Levels in At-Home Agitation Trial The Clinical Trial Vanguard

Tomorrow at ASCO 2026: Roswell Park Experts Present Data Maps Identifying Clinical Trial ‘Deserts’ - Roswell Park Comprehensive Cancer Center

Fri, 29 May 2026 14:00:00 GMT

Tomorrow at ASCO 2026: Roswell Park Experts Present Data Maps Identifying Clinical Trial ‘Deserts’ Roswell Park Comprehensive Cancer Center

Ipatasertib Plus Pembrolizumab Improves ORR in Recurrent/Metastatic HNSCC - Targeted Oncology

Sun, 31 May 2026 17:47:12 GMT

Ipatasertib Plus Pembrolizumab Improves ORR in Recurrent/Metastatic HNSCC Targeted Oncology

OSF HealthCare launches new clinical trials website as resource for cancer patients - WCIA.com

Fri, 29 May 2026 19:29:51 GMT

OSF HealthCare launches new clinical trials website as resource for cancer patients WCIA.com

Khalis Mustafayev: Honored Award for Addressing Urgent AYA Clinical Trial Inequity - Oncodaily

Sun, 31 May 2026 09:01:30 GMT

Khalis Mustafayev: Honored Award for Addressing Urgent AYA Clinical Trial Inequity Oncodaily

ROADS Phase 3 Clinical Trial Data Presented at ASCO26 Show GammaTile® Provides Superior Tumor Control Leading to Patients Living Longer Without Recurrence Compared to Standard of Care in Newly Diagnosed Operable Brain Metastases - PR Newswire

Sat, 30 May 2026 12:05:00 GMT

ROADS Phase 3 Clinical Trial Data Presented at ASCO26 Show GammaTile® Provides Superior Tumor Control Leading to Patients Living Longer Without Recurrence Compared to Standard of Care in Newly Diagnosed Operable Brain Metastases PR Newswire

Neurodegenerative Drug Development Has a 2% Success Rate. Platform Trials Are the Only Honest Response. - The Clinical Trial Vanguard

Fri, 29 May 2026 06:49:00 GMT

Neurodegenerative Drug Development Has a 2% Success Rate. Platform Trials Are the Only Honest Response. The Clinical Trial Vanguard

Zenas BioPharma Submits Obexelimab BLA to FDA for IgG4-Related Disease - The Clinical Trial Vanguard

Sun, 31 May 2026 06:49:44 GMT

Zenas BioPharma Submits Obexelimab BLA to FDA for IgG4-Related Disease The Clinical Trial Vanguard

Targeted Therapy Shows Promising Results Against Rare Soft Tissue Sarcoma - Memorial Sloan Kettering Cancer Center

Sun, 31 May 2026 04:00:00 GMT

Targeted Therapy Shows Promising Results Against Rare Soft Tissue Sarcoma Memorial Sloan Kettering Cancer Center

Daraxonrasib Meets All Primary, Key Secondary Efficacy End Points in Pretreated PDAC - OncLive

Sun, 31 May 2026 13:09:40 GMT

Daraxonrasib Meets All Primary, Key Secondary Efficacy End Points in Pretreated PDAC OncLive

CGT Commercialization Will Succeed Or Fail On Operational Readiness - BioSpectrum Asia

Sun, 31 May 2026 18:34:53 GMT

CGT Commercialization Will Succeed Or Fail On Operational Readiness BioSpectrum Asia

Summit, Akeso drug reduces death by 34% in China lung cancer study. Here’s what it means - Endpoints News

Sun, 31 May 2026 12:00:00 GMT

Summit, Akeso drug reduces death by 34% in China lung cancer study. Here’s what it means Endpoints News

ASCO26: Summit, Akeso claim OS victory for ivonescimab in pivotal Chinese study - FirstWord Pharma

Sun, 31 May 2026 12:15:22 GMT

ASCO26: Summit, Akeso claim OS victory for ivonescimab in pivotal Chinese study FirstWord Pharma

ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34% - Fierce Pharma

Sun, 31 May 2026 12:00:01 GMT

ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34% Fierce Pharma

Akeso, Summit drug extends survival in closely watched lung cancer trial - BioPharma Dive

Sun, 31 May 2026 12:03:37 GMT

Akeso, Summit drug extends survival in closely watched lung cancer trial BioPharma Dive

Congress should not punish drug innovation with weakened patent protections - Washington Times

Sun, 31 May 2026 19:45:58 GMT

Congress should not punish drug innovation with weakened patent protections Washington Times

Immatics Announces Promising Clinical Data for IMA401 in Solid Tumors, Including Head and Neck Cancer, Ahead of ASCO Presentation - Quiver Quantitative

Sun, 31 May 2026 13:10:00 GMT

Immatics Announces Promising Clinical Data for IMA401 in Solid Tumors, Including Head and Neck Cancer, Ahead of ASCO Presentation Quiver Quantitative

Medidata Champions Collaborative Scientific Advancement at ASCO with New Research on Oncology Protocol Optimization and CAR T Efficacy - Dassault Systèmes

Fri, 29 May 2026 09:09:06 GMT

Medidata Champions Collaborative Scientific Advancement at ASCO with New Research on Oncology Protocol Optimization and CAR T Efficacy Dassault Systèmes

New WHO online course strengthens good practices in clinical trials - World Health Organization (WHO)

Fri, 15 May 2026 07:00:00 GMT

New WHO online course strengthens good practices in clinical trials World Health Organization (WHO)

SARC041 Trial: Abemaciclib in Dedifferentiated Liposarcoma - Oncodaily

Sun, 31 May 2026 20:23:50 GMT

SARC041 Trial: Abemaciclib in Dedifferentiated Liposarcoma Oncodaily

Updated Phase 1 Data for IMA401 MAGEA4/8 TCR Bispecific: Clinical Activity and Tolerability in Solid Tumors and Rationale for Combination with IMA402 - Onco'Zine

Sun, 31 May 2026 18:39:43 GMT

Updated Phase 1 Data for IMA401 MAGEA4/8 TCR Bispecific: Clinical Activity and Tolerability in Solid Tumors and Rationale for Combination with IMA402 Onco'Zine

New pill doubles survival in metastatic pancreatic cancer trial - Stock Titan

Sun, 31 May 2026 12:06:00 GMT

New pill doubles survival in metastatic pancreatic cancer trial Stock Titan

Targeted Drug Selpercatinib Greatly Reduces Risk of Recurrence in Early-Stage Lung Cancer - Memorial Sloan Kettering Cancer Center

Sun, 31 May 2026 04:00:00 GMT

Targeted Drug Selpercatinib Greatly Reduces Risk of Recurrence in Early-Stage Lung Cancer Memorial Sloan Kettering Cancer Center

Kelonia Therapeutics Presents Updated First-in-Human Data from Phase 1 inMMyCAR Study of KLN-1010 in vivo BCMA CAR-T Therapy at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting - Business Wire

Sun, 31 May 2026 12:00:00 GMT

Kelonia Therapeutics Presents Updated First-in-Human Data from Phase 1 inMMyCAR Study of KLN-1010 in vivo BCMA CAR-T Therapy at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Business Wire

Poll highlights trust and regulatory concerns over AI in clinical trials - Laboratory News

Sun, 31 May 2026 13:50:24 GMT

Poll highlights trust and regulatory concerns over AI in clinical trials Laboratory News

Perioperative Apalutamide Shifts Standard in Localized, High-Risk Prostate Cancer - CancerNetwork

Sun, 31 May 2026 21:37:44 GMT

Perioperative Apalutamide Shifts Standard in Localized, High-Risk Prostate Cancer CancerNetwork

Hope in cancer clinical trials is what we do not measure - KevinMD.com

Fri, 29 May 2026 19:10:53 GMT

Hope in cancer clinical trials is what we do not measure KevinMD.com

Adjuvant Selpercatinib Significantly Improves EFS in Early-Stage RET Fusion–Positive NSCLC - OncLive

Sun, 31 May 2026 13:39:25 GMT

Adjuvant Selpercatinib Significantly Improves EFS in Early-Stage RET Fusion–Positive NSCLC OncLive

Half of clinical trial professionals cite trust and regulatory gaps as barrier to AI adoption, Pistoia Alliance poll finds - News-Medical

Fri, 29 May 2026 07:38:00 GMT

Half of clinical trial professionals cite trust and regulatory gaps as barrier to AI adoption, Pistoia Alliance poll finds News-Medical

Lexitas acquires Erie Retina Research to expand ophthalmic trials - Eyes On Eyecare

Fri, 29 May 2026 19:45:46 GMT

Lexitas acquires Erie Retina Research to expand ophthalmic trials Eyes On Eyecare

Cancer therapy RP2 shrank tumors in first-in-human trial - Stock Titan

Sun, 31 May 2026 12:00:00 GMT

Cancer therapy RP2 shrank tumors in first-in-human trial Stock Titan

Volunteers help advance medical research through clinical trials - KRCG

Thu, 28 May 2026 16:07:52 GMT

Volunteers help advance medical research through clinical trials KRCG

Betting on biotech: Prediction markets set sights on clinical trials - Fierce Biotech

Thu, 21 May 2026 07:00:00 GMT

Betting on biotech: Prediction markets set sights on clinical trials Fierce Biotech

Colorectal Cancer Alliance and GCAR Announce Collaboration to Advance a Groundbreaking Adaptive Clinical Trial Platform for Colorectal Cancer: KLEOS - PR Newswire

Fri, 29 May 2026 15:00:00 GMT

Colorectal Cancer Alliance and GCAR Announce Collaboration to Advance a Groundbreaking Adaptive Clinical Trial Platform for Colorectal Cancer: KLEOS PR Newswire

Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China - Carroll County Mirror-Democrat

Sun, 31 May 2026 13:06:00 GMT

FDA Clears IND for EOM613 Trial in Cancer Cachexia Patients - The Clinical Trial Vanguard

Sat, 30 May 2026 06:54:36 GMT

FDA Clears IND for EOM613 Trial in Cancer Cachexia Patients The Clinical Trial Vanguard

Immunocore trial: brenetafusp 14.3-month survival in melanoma - Stock Titan

Sun, 31 May 2026 12:00:00 GMT

Immunocore trial: brenetafusp 14.3-month survival in melanoma Stock Titan

Local clinical trials: Groundbreaking research on familiar ground | News, Sports, Jobs - The Express - lockhaven.com

Fri, 29 May 2026 06:34:40 GMT

Local clinical trials: Groundbreaking research on familiar ground | News, Sports, Jobs - The Express lockhaven.com

Experimental hantavirus drug ships to Europe as US passengers offered home quarantine - CIDRAP

Fri, 29 May 2026 19:09:00 GMT

Experimental hantavirus drug ships to Europe as US passengers offered home quarantine CIDRAP

Zhaohui Su: Integrated Biometrics Driving Innovation and Rigor in Clinical Trials - Oncodaily

Sat, 30 May 2026 20:28:23 GMT

Zhaohui Su: Integrated Biometrics Driving Innovation and Rigor in Clinical Trials Oncodaily

Immunocore Reports Promising Phase 1 Data for Brenetafusp in Heavily Pretreated Advanced Melanoma at ASCO 2026 - Quiver Quantitative

Sun, 31 May 2026 12:10:00 GMT

Immunocore Reports Promising Phase 1 Data for Brenetafusp in Heavily Pretreated Advanced Melanoma at ASCO 2026 Quiver Quantitative

ASCO 2026: First Featured Studies Introduce Potential New Standards - Oncology News Central

Sat, 30 May 2026 08:00:00 GMT

ASCO 2026: First Featured Studies Introduce Potential New Standards Oncology News Central

Timeline Mitopure Review: Is Urolithin A Worth It? - The Chalkboard Mag

Sun, 31 May 2026 08:37:57 GMT

Timeline Mitopure Review: Is Urolithin A Worth It? The Chalkboard Mag

World-First Focused Ultrasound Equine Clinical Trial Underway | Newswise - Newswise

Fri, 29 May 2026 23:25:00 GMT

World-First Focused Ultrasound Equine Clinical Trial Underway | Newswise Newswise

Immatics starts dual-target lung cancer trial designed to broaden patient reach - Stock Titan

Sun, 31 May 2026 13:00:00 GMT

Immatics starts dual-target lung cancer trial designed to broaden patient reach Stock Titan

Veterans Affairs announces new MDMA clinical trial; Psilocybin’s antidepressant effects are both rapid and long-lasting - The Microdose

Fri, 29 May 2026 15:31:11 GMT

Veterans Affairs announces new MDMA clinical trial; Psilocybin’s antidepressant effects are both rapid and long-lasting The Microdose

Pfizer’s BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer - Business Wire

Sun, 31 May 2026 12:00:00 GMT

Pfizer’s BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer Business Wire

BXCL501 Shows Efficacy Across Agitation Severity in Phase 3 At-Home Trial - The Clinical Trial Vanguard

Sat, 30 May 2026 06:49:36 GMT

BXCL501 Shows Efficacy Across Agitation Severity in Phase 3 At-Home Trial The Clinical Trial Vanguard

New J&J drug combo delays extra prostate cancer treatment by years - Stock Titan

Sun, 31 May 2026 12:27:00 GMT

New J&J drug combo delays extra prostate cancer treatment by years Stock Titan

Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at - GlobeNewswire

Sun, 31 May 2026 13:00:00 GMT

Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at GlobeNewswire

Revolution Medicines Reports Breakthrough Phase 3 Results for Daraxonrasib in Metastatic Pancreatic Cancer - Quiver Quantitative

Sun, 31 May 2026 12:10:00 GMT

Revolution Medicines Reports Breakthrough Phase 3 Results for Daraxonrasib in Metastatic Pancreatic Cancer Quiver Quantitative

BREAKWATER Cohort 3 Data Support FOLFIRI as a Chemo Backbone With Encorafenib/Cetuximab in BRAF V600E+ mCRC - OncLive

Sun, 31 May 2026 17:00:48 GMT

BREAKWATER Cohort 3 Data Support FOLFIRI as a Chemo Backbone With Encorafenib/Cetuximab in BRAF V600E+ mCRC OncLive

Real-World Outcomes for Mosunetuzumab, Epcoritamab Similar to Trial Findings in rrFL - Cancer Therapy Advisor

Sat, 30 May 2026 04:00:00 GMT

Real-World Outcomes for Mosunetuzumab, Epcoritamab Similar to Trial Findings in rrFL Cancer Therapy Advisor

TG Therapeutics’ Ublituximab Meets Primary Endpoint in Phase 3 RMS Trial - The Clinical Trial Vanguard

Sat, 30 May 2026 06:49:36 GMT

TG Therapeutics’ Ublituximab Meets Primary Endpoint in Phase 3 RMS Trial The Clinical Trial Vanguard

Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting - mykxlg.com

Sun, 31 May 2026 12:00:00 GMT

Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting mykxlg.com

Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma - Investing News Network

Sun, 31 May 2026 14:33:51 GMT

Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma Investing News Network

Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer - Yahoo Finance Singapore

Sun, 31 May 2026 12:06:00 GMT

Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer Yahoo Finance Singapore

Advancing care through clinical trials - Valley Health System

Wed, 20 May 2026 12:46:34 GMT

Advancing care through clinical trials Valley Health System

Lilly drug cuts risk of early-stage RET-positive lung cancer returning by 83% - Stock Titan

Sun, 31 May 2026 12:01:00 GMT

Lilly drug cuts risk of early-stage RET-positive lung cancer returning by 83% Stock Titan

Cancer jab can eradicate entire tumours in patients, trial shows - The Guardian

Sat, 30 May 2026 17:00:00 GMT

Cancer jab can eradicate entire tumours in patients, trial shows The Guardian

Protocol to patient care: The operations powering cancer clinical trials | Stanford Cancer Institute - Stanford Medicine

Wed, 20 May 2026 07:00:00 GMT

Protocol to patient care: The operations powering cancer clinical trials | Stanford Cancer Institute Stanford Medicine

Talazoparib Plus Enzalutamide Cuts Progression Risk by 52% in HRR–Altered mCSPC - Targeted Oncology

Sun, 31 May 2026 15:25:30 GMT

Talazoparib Plus Enzalutamide Cuts Progression Risk by 52% in HRR–Altered mCSPC Targeted Oncology

CEPHEUS Final Analysis: DVRd Sustains Efficacy Benefits in Transplant-Ineligible, Newly Diagnosed Multiple Myeloma - OncLive

Sun, 31 May 2026 17:34:55 GMT

CEPHEUS Final Analysis: DVRd Sustains Efficacy Benefits in Transplant-Ineligible, Newly Diagnosed Multiple Myeloma OncLive